Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.30
-0.06 (-0.45%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 42,466 | 57,245 | 55,684 | 45,067 | 23,568 |
Depreciation & Amortization | 20,605 | 17,058 | 14,841 | 12,636 | 11,824 |
Stock-Based Compensation | 326 | 424 | 407 | 397 | 592 |
Other Adjustments | 18,520 | 21,683 | 14,730 | 19,344 | 18,059 |
Change in Receivables | -6,722 | -10,283 | -8,054 | -5,752 | -17,012 |
Changes in Inventories | -8,601 | -12,753 | -18,445 | -2,654 | -9,912 |
Changes in Accounts Payable | 2,790 | 340 | 3,460 | 23 | 4,412 |
Changes in Other Operating Activities | -12,629 | -27,286 | -17,190 | -10,186 | -3,423 |
Operating Cash Flow | 56,755 | 46,428 | 45,433 | 58,875 | 28,108 |
Operating Cash Flow Growth | 22.24% | 2.19% | -22.83% | 109.46% | -21.27% |
Capital Expenditures | -23,326 | -27,504 | -16,403 | -11,323 | -14,660 |
Sale of Property, Plant & Equipment | 309 | 512 | 1,064 | 82 | 370 |
Purchases of Intangible Assets | -15,099 | -6,894 | -11,032 | -7,543 | -4,389 |
Proceeds from Sale of Intangible Assets | 1,401 | 732 | 21 | - | 2,946 |
Purchases of Investments | -46,769 | -28,809 | -41,660 | -136,171 | -88,972 |
Proceeds from Sale of Investments | 19,602 | 53,610 | 25,944 | 112,805 | 77,771 |
Payments for Business Acquisitions | -3,152 | -53,096 | - | - | -326 |
Other Investing Activities | 1,521 | 3,372 | 1,783 | 777 | 873 |
Investing Cash Flow | -65,513 | -58,077 | -40,283 | -41,373 | -26,387 |
Short-Term Debt Issued | 20,257 | 24,490 | 5,493 | -19,382 | 3,520 |
Net Short-Term Debt Issued (Repaid) | 20,257 | 24,490 | 5,493 | -19,382 | 3,520 |
Long-Term Debt Issued | - | - | 3,800 | - | - |
Long-Term Debt Repaid | -1 | - | -3,800 | - | - |
Net Long-Term Debt Issued (Repaid) | -1 | - | 0 | - | - |
Issuance of Common Stock | 397 | 193 | 805 | 368 | 334 |
Repurchase of Common Stock | - | -1,389 | - | - | - |
Net Common Stock Issued (Repurchased) | 397 | -1,196 | 805 | 368 | 334 |
Common Dividends Paid | -6,659 | -6,662 | -6,648 | -4,979 | -4,146 |
Other Financing Activities | -5,704 | 2,279 | -3,413 | -2,868 | -2,130 |
Financing Cash Flow | 8,290 | 18,911 | -3,763 | -26,861 | -2,422 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,243 | 224 | -59 | 286 | 733 |
Net Cash Flow | -468 | 7,262 | 1,387 | -9,359 | -701 |
Free Cash Flow | 33,429 | 18,924 | 29,030 | 47,552 | 13,448 |
Free Cash Flow Growth | 76.65% | -34.81% | -38.95% | 253.60% | -48.20% |
FCF Margin | 9.95% | 5.81% | 10.40% | 19.34% | 6.27% |
Free Cash Flow Per Share | 40.11 | 22.69 | 34.83 | 57.16 | 16.17 |
Levered Free Cash Flow | 41,945 | 30,889 | 27,440 | 14,181 | 15,329 |
Unlevered Free Cash Flow | 4,159 | -3,963 | 11,360 | 22,337 | 5,720 |